All In Biotech

Drug Trial Radar · NCT07787182

A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease

A Placebo-Controlled, Single- and Multiple-Ascending Dose, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

68

Planned (sponsor's estimate)

Start

Oct 10, 2026

Primary completion

Jan 2028

Study completion Jan 2028

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Aug 26, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to see how safe LY4405094 is and to see how much and how quickly LY4405094 gets into the bloodstream. For healthy participants, the study also looks at how much LY4405094 gets into the fluid around the brain and lasts up to 13 weeks and will include a 4-day stay in the Clinical Research Unit (CRU). For participants with Alzheimer's Disease, the study will also look at levels of a specific Alzheimer's-related protein in the brain and will last up to 25 weeks and will include a 3-day stay in the CRU.

Conditions

  • Healthy Volunteers
  • Alzheimer Disease
  • Amyloid
  • Plaque, Amyloid

Interventions

  • LY4405094Drug

    Administered intravenously (IV)

  • LY4405094Drug

    Administered Subcutaneously (SC)

  • PlaceboDrug

    Administered IV

  • PlaceboDrug

    Administered SC

  • Florbetapir F18Other

    Administered IV

  • Florbetaben F 18Other

    Administered IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationTime frame: Baseline up to 25 Weeks

Locations

19 sites in 3 countries. Site status is shown where the registry gives one.

  • CenExel ACT

    Anaheim, California · Not yet recruiting

  • Irvine Clinical Research

    Irvine, California · Not yet recruiting

  • Collaborative Neuroscience Network - CNS

    Los Alamitos, California · Not yet recruiting

  • Fortrea Clinical Research Unit

    Daytona Beach, Florida · Recruiting

  • K2 Medical Research - The Villages

    Lady Lake, Florida · Not yet recruiting

  • K2 Medical Research

    Maitland, Florida · Not yet recruiting

  • Charter Research

    Orlando, Florida · Not yet recruiting

  • Progressive Medical Research

    Port Orange, Florida · Not yet recruiting

  • Alzheimer's Research and Treatment Center

    Stuart, Florida · Not yet recruiting

  • K2 Medical Research - Tampa

    Tampa, Florida · Not yet recruiting

  • Charter Research

    The Villages, Florida · Not yet recruiting

  • Accel Research Sites - NeuroStudies Clinical Research Unit

    Decatur, Georgia · Not yet recruiting

  • QUEST Research Institute

    Farmington Hills, Michigan · Not yet recruiting

  • Xuanwu Hospital Capital Medical University

    Beijing, China · Not yet recruiting

  • Peking University Third Hospital

    Beijing, China · Not yet recruiting

  • Huashan Hospital, Fudan University

    Minhang District, China · Not yet recruiting

  • Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

    Shanghai, China · Not yet recruiting

  • The University of Tokyo Hospital

    Bunkyō City, Japan · Not yet recruiting

  • National Center for Geriatrics and Gerontology

    Ōbu, Japan · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.